Brief: Motus Gi Announces Improvement Of Pure-Vu® Evs System For Use In Upper Gastrointestinal (Gi) Bleeding Procedures Following Successful Pre-Clinical Tests
21/12/2022 13:04
Dec 21 (Reuters) - Motus GI Holdings Inc MOTS.O :
* MOTUS GI ANNOUNCES IMPROVEMENT OF PURE-VU® EVS SYSTEM FOR
USE IN
UPPER GASTROINTESTINAL (GI) BLEEDING PROCEDURES FOLLOWING
SUCCESSFUL PRE-CLINICAL TESTS
* MOTUS GI HOLDINGS INC - ADDITIONAL PRE-CLINICAL AND
CLINICAL
TESTS OF PURE-VU EVS SYSTEM ARE PLANNED IN 1H 2023
* MOTUS GI HOLDINGS INC - INTENDS TO EVALUATE POTENTIAL
STRATEGIC
DISTRIBUTION AND LICENSING PARTNERSHIPS IN U.S. AND ABROAD
* MOTUS GI HOLDINGS INC - DEVELOPMENT PROGRAM ON TRACK TO
SUBMIT
510(K) APPLICATION TO FDA IN 2H 2023
Source text for Eikon: ID:nGNX9wTlsV
Further company coverage: MOTS.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Motus GI Holdings
See all newsBrief: Motus GI Holdings Inc Continuing To Explore A Range Of Strategic And Financing Alternatives
Brief: Motus Gi Holdings Files Prospectus Related To Resale Of Up To 4.4 Million Shares Of Common Stock, By The Selling Stockholder
Brief: Motus GI Granted A U.S. Patent For Key Feature Embodied By The Pure-Vu System
U.S. STOCKS ON THE MOVE-Chewy, Amgen, Bluebird bio
Brief: Motus Gi Holdings Says Prices Public Offering At $1.50 Per Share